Pythia Cap
Equity Investing & Market Satire
UniQure's long-term value hinges more on FDA approval terms and AMT-130's sales economics than on the coming 4-year data. Even the expert's 40-50% improvement estimate, which refers to around year five, would be highly significant for Huntington's disease, which has no viable alternative; she called the single-shot therapy "a huge step forward." Approval terms remain open, though the FDA's stance seems looser lately, and with no alternative the drug could sell well as it stands today. x.com x.comÂ
uniQure's AMT-130 case looks stronger because, per Peter Mantas, Roche researchers reinforced the natural-history comparator argument. Mantas says objections to using Enroll-HD as a comparator are harder to defend ahead of a pivotal regulatory decision, and that the comparator is central to reimbursement. x.comÂ
uniQure's risk/reward is attractive because $10-12 of cash per share plus the upside implies the market assigns a low chance of approval. Management communication was the core issue rather than a change to the endgame; the unmet need is huge and the company is likely closer to the finish line than the start. The prespecified cUHDRS base and bull case was missed, possibly because of attrition, but being negative here is fundamentally betting the drug doesn't work. x.comÂ
uniQure's risk/reward is too high, as the stock has become a binary bet on regulatory and clinical outcomes. The earlier drop came because the FDA asked for a larger trial, a huge setback, yet the stock has since doubled as investors bet on success given very strong efficacy data. Future moves will hinge on regulatory and clinical catalysts, and the chart shows huge swings all the time. x.comÂ
uniQure offers a much better risk-reward after today's news than before the November setback, as @LogicalThesis points out. As clarity on AMT-130's approval builds, it could return to or surpass its October level of about $70, though the market still has trust issues after what happened. If things turn negative again, the case is over. x.comÂ
ClearPoint Neuro has many irons in the fire beyond uniQure, one of its 60+ partners, which still has a decent probability of BLA acceptance in November. Neurona's MTLE drug and Parkinson's partners are enrolling, and gene and cell therapy delivered into the brain is not going to slow down. x.comÂ
uniQure and ClearPoint Neuro look very bullish on the Wall Street Journal report that President Trump is expected to remove FDA Commissioner Marty Makary. x.comÂ
ClearPoint Neuro would become a cash-flow machine if uniQure's AMT-130 reaches commercial launch, and after today's positive reversal it is a much better risk-reward than before the event, as @LogicalThesis points out. Commercial partners pay more for equipment and consumables than trial partners, and royalties flow straight to the bottom line. With more clarity on approval it could regain or pass its October 2025 peak near $30. Without an anchor commercial partner it is far less attractive. … Show more
Small- and mid-cap biotech looks like one of healthcare's more asymmetric setups after a four-year bear market, as AI speeds drug discovery and Big Pharma faces a patent cliff. Over $300B of pharma revenue goes off patent in the next few years, M&A is already ramping hard as pharma hunts for assets, and many small and mid-cap names still trade at reasonable valuations, making them potential takeover targets. x.comÂ